Methotrexate Orion (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme essential for converting folic acid to its active form. This inhibition reduces the synthesis of nucleotides needed for DNA and RNA production, thereby limiting the growth of rapidly dividing cells and dampening immune responses.

The specific dose of Methotrexate Orion is determined by the prescribing clinician based on the individual’s condition, disease severity, renal function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal harm. It is also generally not recommended during breastfeeding due to potential transfer to milk. Women of child‑bearing potential should use effective contraception and discuss risks with their physician.

To request Methotrexate Orion, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with biologic agents, methotrexate is a small‑molecule oral therapy that is less costly and does not require injection. While biologics target specific cytokines, methotrexate offers broader immunosuppression by interfering with folate metabolism, making it a first‑line option for many rheumatic diseases.

Methotrexate Orion should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, excessive heat and direct sunlight to maintain stability throughout its shelf life.

Methotrexate Orion is taken orally as a tablet, usually with a full glass of water. Depending on the prescribing regimen, it may be taken once weekly or as directed by the healthcare provider. Patients should not split or crush tablets unless instructed.

The most serious risks include bone‑marrow suppression leading to anemia or infection, severe liver toxicity, and pulmonary complications such as interstitial pneumonitis. Prompt medical evaluation is required if symptoms like persistent cough, shortness of breath, jaundice, or unexplained bruising occur.

Methotrexate Orion is contraindicated in individuals with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in pregnant or breastfeeding women. Patients with certain blood disorders should also avoid use unless closely monitored.